Immunic Unveils Lead Asset For Multiple Sclerosis At ECTRIMS

2 min read | September 18, 2024 09:25 AM EDT | By Team Kalkine Media

Google News:

Immunic Unveils Lead Asset For Multiple Sclerosis At ECTRIMS — Image source: Shutterstock

Recent News

Sienna Senior Living Benefits From Canada’s Growing Care Demand

WELL Health Keeps Clinics Busy As Healthcare Demand Grows

Lundin Mining’s Copper Strategy Takes Centre Stage On TSX

Canadian Cannabis Stocks Face A New Strategy Test

Make Kalkine Media
My Trusted Source

Immunic Inc has presented significant data on its primary asset, vidofludimus calcium, at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). This congress, held from September 18 to 20 in Copenhagen, Denmark, has provided a platform for showcasing the drug's potential in the management of multiple sclerosis (MS) within the healthcare sector.

Phase 2 CALLIPER Trial Insights

In the Phase 2 CALLIPER trial, vidofludimus calcium demonstrated a consistent reduction in neurofilament light chain (NfL) levels. This outcome suggests the drug might influence disease progression across various progressive MS subtypes. The results indicate that vidofludimus calcium could have a significant impact on the progression of MS.

Effects on Fatigue and Neuroprotection

The drug's potential to address fatigue in MS patients was also highlighted. Vidofludimus calcium appears to inhibit Epstein-Barr virus (EBV) reactivation, a factor associated with MS-related fatigue. Additionally, preclinical data suggests that vidofludimus calcium may offer neuroprotective benefits, potentially enhancing neuronal survival through Nurr1 activation.

Anti-inflammatory Properties

The data also points to a reduction in pathogenic peripheral T helper cells, indicating a possible pathway for treating MS. This anti-inflammatory effect aligns with the broader profile of vidofludimus calcium as a potential therapeutic agent for MS.

Presentation Details

The findings will be shared through an oral poster presentation and three ePosters during the ECTRIMS event. These presentations will provide further insights into the data generated for vidofludimus calcium.

Statements from Immunic's CEO

Immunic (NASDAQ:IMUX)’s CEO, Dr. Daniel Vitt, emphasized the significance of having four poster presentations at the ECTRIMS Congress. Dr. Vitt expressed enthusiasm about the data, which covers various aspects of vidofludimus calcium, including interim data from the CALLIPER trial, antiviral effects on fatigue, neuroprotective data, and anti-inflammatory effects.

Looking ahead, Dr. Vitt mentioned that the next major update for vidofludimus calcium will be the topline data from the CALLIPER trial, expected in April next year. He highlighted that successful results from this trial, combined with data from the ENSURE program and the drug’s established safety profile, might position vidofludimus calcium distinctively in the market compared to other MS treatments.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Incorporated (Kalkine Media), Business Number: 720744275BC0001 and is available for personal and non-commercial use only. The advice given by Kalkine Media through its Content is general information only and it does not take into account the user’s personal investment objectives, financial situation and specific needs. Users should make their own enquiries about any investment and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media is not registered as an investment adviser in Canada under either the provincial or territorial Securities Acts. Some of the Content on this website may be sponsored/non-sponsored, as applicable, however, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used in the Content unless stated otherwise. The images/music that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.